NeoGenomics (NEO) Reports In-Line Q4 EPS, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to NeoGenomics (NEO) Reports In-Line Q4 EPS, Offers Guidance

NeoGenomics Reports 40% Revenue Growth to $107 Million in the Fourth Quarter

February 27, 2020 7:10 AM EST

Fourth-Quarter 2019 Highlights:

Consolidated revenue increased 39.7% to $106.9 millionClinical Services revenue increased 41.7% to $93.4 million Pharma Services revenue increased 27.5% to $13.5 millionPharma Services backlog increased 31.8% to $130.3 millionCompany issues 2020 financial guidance

FT. MYERS, FL / ACCESSWIRE / February 27, 2020 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced fourth-quarter and full-year 2019 results for the period ended December 31, 2019.

"Our fourth quarter performance concludes a very successful year for NeoGenomics in which our company grew by nearly 50%... More